Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Neoplasm Metastasis 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × SGN-LIV1A × Breast × Clear all
NCT03424005 2026-03-16

Morpheus-panBC

Hoffmann-La Roche

Phase 1/2 Recruiting
792 enrolled
Breast

Breast Neoplasms

NCT03310957 2025-12-12

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Seagen Inc.

Phase 1/2 Completed
185 enrolled 23 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01969643 2023-03-07

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Seagen Inc.

Phase 1 Completed
290 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡